首页> 美国卫生研究院文献>Journal of the Boston Society of Medical Sciences >Combined Array Comparative Genomic Hybridization and Tissue Microarray Analysis Suggest PAK1 at 11q13.5-q14 as a Critical Oncogene Target in Ovarian Carcinoma
【2h】

Combined Array Comparative Genomic Hybridization and Tissue Microarray Analysis Suggest PAK1 at 11q13.5-q14 as a Critical Oncogene Target in Ovarian Carcinoma

机译:联合的阵列比较基因组杂交和组织芯片分析表明在卵巢癌中11q13.5-q14的PAK1是重要的致癌基因靶标。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Amplification of chromosomal regions leads to an increase of DNA copy numbers and expression of oncogenes in many human tumors. The identification of tumor-specific oncogene targets has potential diagnostic and therapeutic implications. To identify distinct spectra of oncogenic alterations in ovarian carcinoma, metaphase comparative genomic hybridization (mCGH), array CGH (aCGH), and ovarian tumor tissue microarrays were used in this study. Twenty-six primary ovarian carcinomas and three ovarian carcinoma cell lines were analyzed by mCGH. Frequent chromosomal overrepresentation was observed on 2q (31%), 3q (38%), 5p (38%), 8q (52%), 11q (21%), 12p (21%), 17q (21%), and 20q (52%). The role of oncogenes residing in gained chromosomal loci was determined by aCGH with 59 genetic loci commonly amplified in human tumors. DNA copy number gains were most frequently observed for >PIK3CA on 3q (66%), >PAK1 on 11q (59%), >KRAS2 on 12p (55%), and >STK15 on 20q (55%). The 11q13-q14 amplicon, represented by six oncogenes (>CCND1, >FGF4, >FGF3, >EMS1, >GARP, and >PAK1) revealed preferential gene copy number gains of >PAK1, which is located at 11q13.5-q14. Amplification and protein expression status of both PAK1 and CCND1 were further examined by fluorescence >in situ hybridization and immunohistochemistry using a tissue microarray consisting of 268 primary ovarian tumors. >PAK1 copy number gains were observed in 30% of the ovarian carcinomas and PAK1 protein was expressed in 85% of the tumors. >PAK1 gains were associated with high grade (>P < 0.05). In contrast, >CCND1 gene alterations and protein expression were less frequent (10.6% and 25%, respectively), suggesting that the critical oncogene target of amplicon 11q13–14 lies distal to >CCND1. This study demonstrates that aCGH facilitates further characterization of oncogene candidates residing in amplicons defined by mCGH.
机译:染色体区域的扩增导致许多人肿瘤中DNA拷贝数的增加和癌基因的表达。肿瘤特异性癌基因靶标的鉴定具有潜在的诊断和治疗意义。为了鉴定卵巢癌的致癌性改变的独特光谱,本研究使用了中期比较基因组杂交(mCGH),阵列CGH(aCGH)和卵巢肿瘤组织微阵列。通过mCGH分析了26种原发性卵巢癌和3种卵巢癌细胞系。在2q(31%),3q(38%),5p(38%),8q(52%),11q(21%),12p(21%),17q(21%)和20q处观察到频繁的染色体过度表达(52%)。癌基因在获得的染色体基因座中的作用由aCGH确定,该基因座具有人类肿瘤中通常扩增的59个遗传基因座。在3q(66%),> PAK1 ,11q(59%),> KRAS2 (在12p)上观察到最常见的DNA拷贝数增加是> PIK3CA 55%)和> STK15 (20q)(55%)。 11q13-q14扩增子,由六个癌基因(> CCND1 ,> FGF4 ,> FGF3 ,> EMS1 ,> GARP 和> PAK1 )显示了优先获得的> PAK1 的基因拷贝数,位于11q13.5-q14。使用由268个原发性卵巢肿瘤组成的组织芯片,​​通过荧光原位杂交和免疫组织化学进一步检查了PAK1和CCND1的扩增和蛋白质表达状态。在30%的卵巢癌中观察到> PAK1 拷贝数增加,在85%的肿瘤中表达了PAK1蛋白。 > PAK1 的获得与高分相关(> P <0.05)。相反,> CCND1 基因改变和蛋白质表达的频率较低(分别为10.6%和25%),这表明扩增子11q13–14的关键致癌基因靶标位于> CCND1远端 。这项研究表明,aCGH有助于进一步表征驻留在mCGH定义的扩增子中的致癌基因候选物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号